AP2781A - Oxidized proteins, their biological activity, and therapeutic and diagnostic measures, which are derived from the active mechansim, from the use of these porteins or from the inhibition thereof - Google Patents

Oxidized proteins, their biological activity, and therapeutic and diagnostic measures, which are derived from the active mechansim, from the use of these porteins or from the inhibition thereof

Info

Publication number
AP2781A
AP2781A AP2009004857A AP2009004857A AP2781A AP 2781 A AP2781 A AP 2781A AP 2009004857 A AP2009004857 A AP 2009004857A AP 2009004857 A AP2009004857 A AP 2009004857A AP 2781 A AP2781 A AP 2781A
Authority
AP
ARIPO
Prior art keywords
porteins
mechansim
inhibition
therapeutic
derived
Prior art date
Application number
AP2009004857A
Other versions
AP2009004857A0 (en
Inventor
Beate Kehrel
Original Assignee
Hamburger Stiftung Zur Forderung Van Wissenschaft Und Kultur
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE10051983A external-priority patent/DE10051983A1/en
Priority claimed from DE2001148624 external-priority patent/DE10148624A1/en
Application filed by Hamburger Stiftung Zur Forderung Van Wissenschaft Und Kultur filed Critical Hamburger Stiftung Zur Forderung Van Wissenschaft Und Kultur
Publication of AP2009004857A0 publication Critical patent/AP2009004857A0/en
Application granted granted Critical
Publication of AP2781A publication Critical patent/AP2781A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Virology (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Transplantation (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • AIDS & HIV (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Zoology (AREA)
  • Oncology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
AP2009004857A 2000-10-20 2001-10-19 Oxidized proteins, their biological activity, and therapeutic and diagnostic measures, which are derived from the active mechansim, from the use of these porteins or from the inhibition thereof AP2781A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE10051983A DE10051983A1 (en) 2000-10-20 2000-10-20 Medicaments useful e.g. for preventing thrombosis, inhibiting transplant rejection or treating chronic inflammatory reactions comprises agents inhibiting binding of oxidized proteins to CD36,
DE2001148624 DE10148624A1 (en) 2001-10-02 2001-10-02 Medicaments useful e.g. for preventing thrombosis, inhibiting transplant rejection or treating chronic inflammatory reactions comprises agents inhibiting binding of oxidized proteins to CD36,
PCT/EP2001/012129 WO2002032445A2 (en) 2000-10-20 2001-10-19 Inhibition of the interaction between oxidized proteins and cd36 or the active mechanism thereof

Publications (2)

Publication Number Publication Date
AP2009004857A0 AP2009004857A0 (en) 2009-06-30
AP2781A true AP2781A (en) 2013-10-31

Family

ID=26007431

Family Applications (2)

Application Number Title Priority Date Filing Date
AP2009004857A AP2781A (en) 2000-10-20 2001-10-19 Oxidized proteins, their biological activity, and therapeutic and diagnostic measures, which are derived from the active mechansim, from the use of these porteins or from the inhibition thereof
APAP/P/2003/002795A AP2034A (en) 2000-10-20 2001-10-19 Oxidized proteins, their biological activity, and therapeutic and diagnostic measures, which are derived from the active mechanism, from the use of these proteins or from the inhibition thereof.

Family Applications After (1)

Application Number Title Priority Date Filing Date
APAP/P/2003/002795A AP2034A (en) 2000-10-20 2001-10-19 Oxidized proteins, their biological activity, and therapeutic and diagnostic measures, which are derived from the active mechanism, from the use of these proteins or from the inhibition thereof.

Country Status (13)

Country Link
EP (2) EP1328289B1 (en)
JP (1) JP4881535B2 (en)
AP (2) AP2781A (en)
AT (1) ATE406908T1 (en)
AU (1) AU2002215032A1 (en)
CA (1) CA2453140C (en)
CY (1) CY1110418T1 (en)
DE (1) DE50114289D1 (en)
DK (1) DK1328289T3 (en)
ES (1) ES2307662T3 (en)
OA (1) OA12431A (en)
PT (1) PT1328289E (en)
WO (1) WO2002032445A2 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2375601T3 (en) * 2003-04-25 2012-03-02 Hamburger Stiftung Zur Förderung Von Wissenschaft Und Kultur FIGHT AGAINST INFECTIONS BY IH VIRUSES WITH BLOOD PLASMA OXIDIZED HUMAN NEO WITH HYPOCLOROUS ACID.
EP3725324A1 (en) * 2005-09-16 2020-10-21 Cornell Research Foundation, Inc. Aromatic-cationic peptide for use in a method for reducing cd36 expression
JP2010235447A (en) * 2007-07-30 2010-10-21 Igaku Seibutsugaku Kenkyusho:Kk Inflammatory cytokine inhibitors
DE102010043733A1 (en) 2010-11-10 2012-05-10 Oxprotect Gmbh Unloaded PEGylated liposomes for use as medicaments for the prophylaxis and therapy of hemorrhagic and thromboembolic disorders
DE102011003936A1 (en) 2011-02-10 2012-08-16 Oxprotect Gmbh Use of proteins / peptides that bind to GRP78 (BIP) in laboratory methods for monitoring platelet aggregation inhibitors
DE102011003944A1 (en) 2011-02-10 2012-08-16 Oxprotect Gmbh Detection and removal of misfolded proteins / peptides
US10531655B2 (en) 2011-12-02 2020-01-14 The Regents Of The University Of California Reperfusion protection solution and uses thereof

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991004744A1 (en) * 1989-10-06 1991-04-18 The Beth Israel Hospital Association Methods and apparatus for treating disease states using oxidized lipoproteins
WO1991010684A1 (en) * 1990-01-08 1991-07-25 Schering Corporation Oxidized variants of gm-csf
WO1992001467A1 (en) * 1990-07-18 1992-02-06 The Beth Israel Hospital Association Method for treating viral infections using oxidized lipoproteins
US5192264A (en) * 1989-10-06 1993-03-09 The Beth Israel Hospital Association Methods and apparatus for treating disease states using oxidized lipoproteins
WO1997021443A1 (en) * 1995-12-14 1997-06-19 Mark Borisovich Balazovskiy Cytokine and hemopoietic factor endogenous production enhancer and methods of use thereof
WO1999049883A2 (en) * 1998-03-28 1999-10-07 The University Court Of The University Of Glasgow Oxidized thymosin beta 4

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3819923A1 (en) * 1988-06-11 1989-12-21 Behringwerke Ag FIBRINE (OGEN) DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF AND THEIR USE
EP0728019A4 (en) 1993-11-08 1999-07-07 Peptide Delivery Systems Pty L Labelled diagnostic compositions and methods of their use
CA2294355C (en) 1997-06-20 2006-11-28 Leuven Research & Development Vzw Assays, antibodies, and standards for detection of oxidized and mda-modified low density lipoproteins
CA2348685A1 (en) * 1998-11-06 2000-05-18 Emory University Biomarkers for oxidative stress
DE10045047A1 (en) * 2000-09-12 2002-03-21 Beate Kehrel Medicament containing activated antithrombin III

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991004744A1 (en) * 1989-10-06 1991-04-18 The Beth Israel Hospital Association Methods and apparatus for treating disease states using oxidized lipoproteins
US5192264A (en) * 1989-10-06 1993-03-09 The Beth Israel Hospital Association Methods and apparatus for treating disease states using oxidized lipoproteins
WO1991010684A1 (en) * 1990-01-08 1991-07-25 Schering Corporation Oxidized variants of gm-csf
WO1992001467A1 (en) * 1990-07-18 1992-02-06 The Beth Israel Hospital Association Method for treating viral infections using oxidized lipoproteins
WO1997021443A1 (en) * 1995-12-14 1997-06-19 Mark Borisovich Balazovskiy Cytokine and hemopoietic factor endogenous production enhancer and methods of use thereof
WO1999049883A2 (en) * 1998-03-28 1999-10-07 The University Court Of The University Of Glasgow Oxidized thymosin beta 4

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
DAWSON DAVID W ET AL: "CD36 mediates the in vitro inhibitory effects of thrombospondin-1 on endothelial cells." JOURNAL OF CELL BIOLOGY, Bd. 138, Nr. 3, 1997, Seiten 707-717, XP002215771 ISSN: 0021-9525 *

Also Published As

Publication number Publication date
PT1328289E (en) 2008-12-10
CA2453140C (en) 2016-01-05
AP2034A (en) 2009-08-28
AP2009004857A0 (en) 2009-06-30
AU2002215032A1 (en) 2002-04-29
WO2002032445A2 (en) 2002-04-25
DE50114289D1 (en) 2008-10-16
EP1328289A2 (en) 2003-07-23
WO2002032445A3 (en) 2003-04-17
JP2004511526A (en) 2004-04-15
OA12431A (en) 2006-04-19
HK1057857A1 (en) 2004-04-23
AP2003002795A0 (en) 2003-06-30
CA2453140A1 (en) 2002-04-25
ES2307662T3 (en) 2008-12-01
EP1328289B1 (en) 2008-09-03
CY1110418T1 (en) 2015-04-29
ATE406908T1 (en) 2008-09-15
JP4881535B2 (en) 2012-02-22
EP1994941A2 (en) 2008-11-26
DK1328289T3 (en) 2008-12-15
EP1994941A3 (en) 2012-07-25

Similar Documents

Publication Publication Date Title
DE60233157D1 (en) TWO-CHAMBER PACEMAKER SYSTEM FOR THE DIAGNOSIS AND REMEDY OF ARRHYTHMIES
DE50014699D1 (en) Medical instrument for the preparation of tissue
ATE318590T1 (en) DRUG COMBINATIONS (E.G. CHLORPROMAZINE AND PENTAMIDINE) FOR THE THERAPY OF NEOPLASTIC DISEASES
WO2002040634A3 (en) Expression miniarrays and uses thereof
AU2002216273A1 (en) Proteins, genes and their use for diagnosis and treatment of kidney response
AU2002226690A1 (en) Drugs for the diagnosis of tissue-reproductive activity or the treatment of proliferative diseases
IL143699A0 (en) Use of polypeptides or nucleic acids for the diagnosis or treatment of skin disorders and wound healing and for the identification of pharmacologically active substances
NO20013507L (en) Preparations for the treatment of inflammatory reactions
AU2002219229A1 (en) Means for the diagnosis and therapy of CTCL
BR0014560B1 (en) use of a tissue treatment composition.
AU2002303261A8 (en) Gene brcc2 and diagnostic and therapeutic uses thereof
GB0019302D0 (en) Biological materials and the use thereof for the treatment of disease
DK1353948T3 (en) Soluble biological analogs for beta-amyloid peptide
AU6425800A (en) Agents for the diagnosis, prognosis and treatment of malignant diseases
AP2009004857A0 (en) Oxidized proteins, their biological activity, and therapeutic and diagnostic measures,which are derived from the active mechanism, from the use of these proteins or from the inhibition thereof
MXPA03006776A (en) Use of il-18 inhibitors for the treatment and/or prevention of heart disease.
ZA200203269B (en) Nucleic acids of the human ABC1 gene and their therapeutic and diagnostic application.
AU2003263036A8 (en) Span-xb gene and protein for the diagnosis and treatment of cancer
AU4204700A (en) Compounds and methods for the diagnosis and treatment of (b. microti) infection
AU2001233954A1 (en) Proteins, genes and their use for diagnosis and treatment of schizophrenia
AU2001240820A1 (en) Proteins, genes and their use for diagnosis and treatment of vascular dementia
AU2002322301A1 (en) Methods for the diagnosis and treatment of cardiac tissue rejection
WO2000063348A3 (en) Pharmaceutical composition comprising pim-activated nkt cells, and therapeutic use thereof
MXPA02002864A (en) Self cleaving rna sequences and their use for the control of protein synthesis.
GB9908059D0 (en) Diagnosis and treatment of diseases